Chinese EV stocks drop as Tesla’s earnings miss, General Motors delays EV plans

Chinese EV stocks drop as Tesla’s earnings miss, General Motors delays EV plans


Spectators are looking at BYD Song L electric cars at the 21st Changchun International Automobile Expo in Changchun, Jilin province, China, on July 17, 2024. (Photo by Costfoto/NurPhoto via Getty Images)

Nurphoto | Nurphoto | Getty Images

Shares of major Chinese electric vehicle companies dropped Wednesday after U.S. giant Tesla‘s earnings fell short of analysts’ estimates and General Motors delayed its EV plans.

Hong Kong-listed shares of Xpeng lost as much as 5.74% while Nio‘s stock tumbled as much as 5.26% on Wednesday.

Li Auto‘s shares dropped as much as 3.99% while BYD, Zhejiang Leapmotor and SAIC Motor slid as much as 3.1%, 5.34% and 1.02%, respectively on Wednesday.

In the U.S., shares of Xpeng and Nio closed 6.67% and 4.48% lower respectively on Tuesday.

EV hype has been dwindling, as automakers from Tesla to General Motors scale back or delay their EV plans.

On Tuesday, Tesla reported a second straight quarterly decline in revenue, down 7% to $19.9 billion, from $21.27 billion in the same period a year ago. Tesla shares closed 2.04% lower.

CEO Elon Musk said in the firm’s earnings call on Tuesday that Tesla will host a robotaxi unveiling event on Oct. 10, after originally saying the event would take place on Aug. 8.

When asked about the timeline of “the first robotaxi ride,” Musk said he would be “shocked if we cannot do it next year.” He also noted that his predictions have been “overly optimistic in the past.”

Separately, General Motors on Tuesday said it was delaying further a second U.S. electric truck plant and the Buick brand’s first EV.

Investors were spooked by the pullbacks in growth businesses and General Motors’ shares closed 6.42% lower on Tuesday despite solid financial results.

Tesla has 'a lot to prove' if it's positioning itself as an AI company, says fmr. board member Steve Westly

GM also said it was indefinitely putting on hold the production of its Cruise Origin autonomous vehicle, and that it was making efforts to restructure a joint venture in China with SAIC amid continuing losses.

The EV industry is facing a reality check, after years of buzz which saw automakers putting out optimistic sales forecasts for EV models and announcing ambitious growth targets.

Surging raw material costs, high interest rates and other factors have made EVs much more expensive to produce, as compared to their traditional counterparts.

– CNBC’s Michael Wayland contributed to this report.



Source

Finland’s IQM to become one of Europe’s first listed quantum companies at .8 billion valuation
World

Finland’s IQM to become one of Europe’s first listed quantum companies at $1.8 billion valuation

European startup IQM is aiming to build powerful quantum computers to rival the likes of Google and IBM. IQM Finland-based quantum computing startup IQM announced plans Monday to become one of Europe’s first publicly listed companies in the sector. IQM will merge with special purpose acquisition company (SPAC), Real Asset Acquisition Corp. (RAAQ) as part […]

Read More
Treasury yields hold steady as investors weigh new Trump tariffs
World

Treasury yields hold steady as investors weigh new Trump tariffs

U.S. Treasury yields were little changed to start the week as investors weighed President Donald Trump’s latest tariffs, after the Supreme Court struck down much of the duties on Friday. At 6:03 a.m. ET, the 10-year Treasury yield was down 1 basis point at 4.075%. The 30-year Treasury bond yield was also less than 1 basis point lower […]

Read More
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly’s in trial
World

Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly’s in trial

Novo Nordisk stock fell over 10% Monday after it said its next-generation weight loss drug didn’t meet its primary target. The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly‘s rival drug tirzepatide after 84 weeks, Novo said in a statement Monday morning. Eli Lilly‘s stock […]

Read More